- Home
- BIRD vs PASG Comparison
BIRD vs PASG Comparison
Compare BIRD & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | PASG |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | 24 |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 26.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BIRD | PASG |
|---|---|---|
| Price | $3.20 | $7.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $11.00 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 73.7K | 27.8K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $189,757,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.45 | $0.28 |
| 52 Week High | $12.84 | $20.00 |
Technical Indicators
Market Signals| Indicator | BIRD | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 34.68 |
| Support Level | $2.45 | $6.71 |
| Resistance Level | $3.36 | $7.72 |
| Average True Range (ATR) | 0.33 | 0.75 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 44.59 | 5.70 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.